▲ Peaking
Business
Silence Therapeutics Enters into Agreement to be Acquired by Merck KGaA, Darmstadt, Germany
Merck KGaA’s $1.3 billion bid for Silence Therapeutics signals a high‑stakes push into RNA drug platforms.
Rna Therapeutics
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Rna Therapeutics
This hub groups 3 separate news trends connected to Rna Therapeutics, spanning August 21, 2026 through October 19, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 19 article observations and 19 source signals, led by Business, Science coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
ARPA-H awards $125M for manufacturing custom RNA therapies on demand
The US government is investing heavily in on-demand RNA therapies, but the path to market is not straightforward.
◼ Archived
Science
🔮 fades ✓
New lipid nanoparticle delivers capped circular RNA for longer-lasting gene expression
A new lipid nanoparticle promises to extend the duration of gene expression, potentially revolutionizing RNA therapies.